New York, USA – November 15, 2024 – Recently, a scientist from Pennsylvania State University found they could achieve up to a 92 percent endothelial cell conversion rate by applying the two proteins SRY-box 17 (SOX17) and fibroblast growth factor 2 (FGF2) to human pluripotent stem cells (hiPSCs). This finding is undoubtedly good news for scientists dedicated to stem cell research and gives future stem cell research a new direction. Specializing in this field for decades, Creative Biolabs is the global leader in stem cell therapy research. It is committed to providing comprehensive iPSC services and products to support researchers making breakthroughs.
“We’re excited to hear this news, and I believe it encourages scientists working in this field while also encouraging us to develop high-quality FGF2 proteins to meet their demands of research projects.” said a scientist from Creative Biolabs. “We offer two kinds of FGF2 products, including high-bioactivity recombinant human FGF2 and a more stabilized version of FGF2 called FGF2 STAB with high purity, high bioactivity, high batch consistency, and long half-life to our worldwide clients, perfectly fitting human iPSC culture system.”
This company also highlights a wide range of iPSC-related services to fully support your research in stem cell therapy, including neural stem cell differentiation and CNS disease modeling services. Their proprietary technology can differentiate your specific stem cells into a variety of neural cell types, including neurons, astrocytes, oligodendrocytes, etc., according to your research needs, ensuring high purity and yield in neural cells and decreasing the chance of experimental variation brought by undesired cell types.
“We’ve optimized our neuroscience in vitro models platforms with advanced technologies, high-quality facilities, and professional experts. With the advanced platforms, our scientists can design and implement genetically modified animal models or in vitro models of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, or ALS, providing reliable support to their studies,” added the scientist.
Standing at the forefront of stem cell research, Creative Biolabs maintains its minds to advancing this field. Learn more about comprehensive services and high-quality products, please go to https://www.creative-biolabs.com/stem-cell-therapy.
About Creative Biolabs
As a CRO specializing in stem cell therapy research, Creative Biolabs has a team of experienced scientists and well-treated staff and has established advanced development platforms. Concentrating on providing a wide range of early development services, such as neural stem cell differentiation, in vitro modeling services, and iPSC-derived services, Creative Biolabs works with global clients to find the best way to conquer challenges in stem cell therapy research.
Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-830-6441Country: United StatesWebsite: https://www.creative-biolabs.com/stem-cell-therapy
